Sevabertinib alone produced sturdy and lasting responses in sufferers with HER2-mutant superior non–small cell lung most cancers (NSCLC), working in each first-line and beforehand handled settings, based on the part 1/2 SOHO-01 trial introduced on the 2025 European Society for Medical Oncology Congress and revealed within the New England Journal of Medication.
In cohort D (81 sufferers), which included sufferers who have been beforehand handled, the target response price (ORR) was 64%, with 2% reaching full responses (CRs), 62% reaching partial responses (PRs), 25% having steady illness, 7% having progressive illness, and 4% not being evaluable. The illness management price (DCR) was 81%.
The median length of response (DOR) was 9.2 months, with a 12-month DOR price of 42%; the median progression-free survival (PFS) was 8.3 months, with a 12-month PFS price of 44%.
With a median follow-up of 13.8 months (vary, 1-32), the median length of therapy (DOT) was 9.9 months. A complete of 30% of sufferers had ongoing therapy, 20% had a therapy length of greater than 15 months, and responses have been maintained after dose reductions or interruptions.
Subgroup analyses revealed that ORR was constant throughout all subgroups, akin to age, intercourse, race, variety of earlier systemic therapies, presence of baseline mind metastases, and receipt of prior platinum chemotherapies.
In sufferers with non-squamous NSCLC and HER2 tyrosine kinase area (TKD) mutations (70 sufferers), the ORR by BICR was 71%, and the median PFS was 9.6 months. In sufferers with HER2 Y772_A775dupYVMA alterations (49 sufferers), the ORR by BICR was 78%; in these with YVMA, the median PFS was 12.2 months, and in these with different TKD mutations, the median PFS was 7 months.
Moreover, in cohort E, which included sufferers who obtained prior therapy with HER2 antibody drug conjugates (55 sufferers), the ORR by BICR was 38%, with 5% reaching CRs, 33% reaching PRs, 42% having steady illness, 13% having progressive illness, and seven% not being evaluable; the DCR was 71%.
The median DOR was 8.5 months, with a 12-month DOR price of 29%, and the median PFS was 5.5 months, with a 12-month PFS price of 28%. The median follow-up was 11.6 months.
In cohort F, which enrolled sufferers who have been treatment-naïve (73 sufferers), the ORR by BICR was 71%, with 4% reaching CRs, 67% reaching PRs, 22% having steady illness, 3% having progressive illness, and 1% not being evaluable. The DCR was 89%.
The median DOR was 11.0 months, and the median PFS was NE. The median follow-up was 9.9 months.
Additional, mind metastases have been current in 22% of sufferers in cohort D, 27% of cohort E, and 12% of cohort F. An evaluation demonstrated systemic responses have been related in sufferers with and with out mind metastases. In cohort D, sufferers with and with out mind metastases had ORRs of 61% and 65%, respectively; in cohort E, the ORRs have been 27% and 43%; and in cohort F, the ORRs have been 78% and 70%.
In sufferers who had mind metastases at baseline in cohorts D, E, and F, post-baseline development within the mind was noticed in 22%, 20%, and 0%, respectively. In these with no mind metastases at baseline in cohorts D, E, and F, post-baseline development within the mind was noticed in 6%, 5% and three%, respectively.
“Sevabertinib demonstrated sturdy and sturdy responses in sufferers with HER2-mutant NSCLC in each pretreated and first-line settings. The commonest [adverse] impact was diarrhea, which was manageable; there have been no reported circumstances of interstitial lung illness (ILD) or pneumonitis,” stated presenting research writer Dr. Xiuning Le, affiliate professor within the Division of Thoracic/Head and Neck Medical Oncology of the Division of Inside Medication on the College of Texas MD Anderson Most cancers Middle, and coauthors, within the presentation. “These knowledge help sevabertinib as a possible new focused remedy for sufferers with HER2-mutant NSCLC.”
SOHO-01 enrolled sufferers with superior NSCLC with HER2 or EGFR mutations; this evaluation included knowledge from the cohorts of sufferers with HER2 mutations. Cohort D enrolled sufferers who have been beforehand handled, however naïve to HER2-targeted therapies; cohort E enrolled sufferers who have been beforehand handled with HER2-targeted ADCs; and cohort F enrolled sufferers who have been naïve to systemic remedy for superior illness.
Throughout cohorts D, E, and F, the median age of sufferers was 60 years, 65 years, and 65 years, respectively, and 62%, 64%, and 78% had by no means smoked. Activating Y772_A775dupYVMA HER2 mutations have been noticed in 60%, 73%, and 79%, respectively, and 90%, 95%, and 97% had HER2 TKD mutations. Enhertu (fam-trastuzumab deruxtecan-nxki) was obtained as earlier anti-cancer remedy by 2%, 75% and 0%, and chemotherapy was obtained by 96%, 80%, and eight%.
Remedy consisted of accelerating oral doses of sevabertinib from 10 mg as soon as each day to 40 milligrams twice each day, to determine the advisable dose for enlargement.
The first finish level of the extension part was ORR. Secondary finish factors included DOR, DCR, PFS and security and tolerability.
Concerning security, drug-related unwanted effects occurred in 69% of cohort D, 100% of cohort E, and 97% of cohort F; grade 3 (extreme) unwanted effects have been reported in 36%, 31%, and 21%. Notably, grade 3 diarrhea unwanted effects occurred in 23% of cohort D, 11% of cohort E, and 5% of cohort F. ILD or pneumonitis was not noticed in any sufferers.
Biomarker knowledge from SOHO-01 are being shared in a poster at ESMO on October 18, 2025.
Sevabertinib can also be being evaluated as a first-line remedy for sufferers with regionally superior or metastatic NSCLC with HER2 mutations within the ongoing part 3 SOHO-02 trial.
References
- “Sevabertinib (BAY 2927088) in superior HER2-mutant non-small cell lung most cancers: outcomes from the SOHO-01 research” by Dr. Le, et al., introduced on the European Society for Medical Oncology Congress
- “Sevabertinib in superior HER2-mutant non–small-cell lung most cancers” by Dr. Le, et al., New England Journal of Medication
- “Molecular components and ctDNA dynamics related to scientific outcomes in sufferers with HER2-mutant NSCLC handled with sevabertinib: exploratory evaluation of the SOHO-01 research” by Dr. Girard, et al., introduced on the European Society for Medical Oncology Congress
For extra information on most cancers updates, analysis and training,
